Cargando…
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the da...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933613/ https://www.ncbi.nlm.nih.gov/pubmed/27340254 http://dx.doi.org/10.1177/1753465816652083 |